MacroGenics Inc. (MGNX) Financial Statements (2025 and earlier)

Company Profile

Business Address 9704 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments83,93280,355100,95689,898108,758224,264
Cash and cash equivalents83,93280,355100,95689,898108,758224,264
Receivables6,1917,21910,36725,3116,41036,160
Inventory, net of allowances, customer advances and progress billings1,1151,2481,2211,0661,4431,409
Inventory1,1151,2481,2211,0661,4431,409
Prepaid expense   9,946   
Other undisclosed current assets65,713113,753128,849175,044138,06427,110
Total current assets:156,951202,575251,339291,319254,675288,943
Noncurrent Assets
Operating lease, right-of-use asset22,61723,22923,84624,63225,50126,394
Property, plant and equipment20,38321,29621,84722,63424,09126,783
Other noncurrent assets1,1861,1851,3861,3871,3861,378
Total noncurrent assets:44,18645,71047,07948,65350,97854,555
TOTAL ASSETS:201,137248,285298,418339,972305,653343,498
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities29,68228,84230,68228,78131,32331,947
Accounts payable5,23610,6946,4433,3033,7953,759
Accrued liabilities24,44618,14824,23925,47827,52828,188
Deferred revenue23,81822,83721,65118,5849,6719,249
Other undisclosed current liabilities4,4064,0853,7753,9264,1614,418
Total current liabilities:57,90655,76456,10851,29145,15545,614
Noncurrent Liabilities
Liabilities, other than long-term debt85,41286,36789,69794,70188,95488,394
Deferred revenue55,50356,18259,24364,26058,53858,006
Other liabilities258258258258258258
Operating lease, liability29,65129,92730,19630,18330,15830,130
Other undisclosed noncurrent liabilities      100,222
Total noncurrent liabilities:85,41286,36789,69794,70188,954188,616
Total liabilities:143,318142,131145,805145,992134,109234,230
Equity
Equity, attributable to parent57,819106,154152,613193,980171,544109,268
Common stock627626621620619618
Additional paid in capital1,267,8221,260,5051,254,7501,250,0741,245,2311,240,345
Accumulated other comprehensive income (loss)(24)(35)(6)(34)(72)8
Accumulated deficit(1,210,606)(1,154,942)(1,102,752)(1,056,680)(1,074,234)(1,131,703)
Total equity:57,819106,154152,613193,980171,544109,268
TOTAL LIABILITIES AND EQUITY:201,137248,285298,418339,972305,653343,498

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues10,7979,10410,72010,39713,13624,496
Cost of revenue(2,823)(2,116)(163)(3,359)(1,177)(3,523)
Cost of goods and services sold(176)(270)(163)(85)(258)(113)
Gross profit:7,9746,98810,5577,03811,95920,973
Operating expenses(66,155)(60,738)(59,911)(42,540)(56,921)(59,399)
Operating income (loss):(58,181)(53,750)(49,354)(35,502)(44,962)(38,426)
Nonoperating income
(Other Nonoperating income)
2,5232,6933,2823,0562,275417
Interest and debt expense (6)(1,133)  (774) 
Net income (loss):(55,664)(52,190)(46,072)(32,446)(43,461)(38,009)
Other undisclosed net income attributable to parent    50,000100,930 
Net income (loss) available to common stockholders, diluted:(55,664)(52,190)(46,072)17,55457,469(38,009)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net income (loss):(55,664)(52,190)(46,072)(32,446)(43,461)(38,009)
Comprehensive income (loss):(55,664)(52,190)(46,072)(32,446)(43,461)(38,009)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent11(29)2950,038100,85013
Comprehensive income (loss), net of tax, attributable to parent:(55,653)(52,219)(46,043)17,59257,389(37,996)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: